Company: DNLI
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001714899-25-000193
Chunk: 181

Company: Denali Therapeutics Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 181
---
ITEM 1.    FINANCIAL STATEMENTS

Denali Therapeutics Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except share amounts)

September 30, 2025December 31, 2024AssetsCurrent assets:Cash and cash equivalents$90,963 $174,960 Short-term marketable securities757,241 657,371 Prepaid expenses and other current assets34,394 32,105 Total current assets882,598 864,436 Long-term marketable securities24,703 359,373 Property and equipment, net53,732 55,236 Finance lease right-of-use asset49,447 47,533 Operating lease right-of-use asset20,035 22,861 Other non-current assets25,106 24,741 Total assets$1,055,621 $1,374,180 Liabilities and stockholders' equity Current liabilities:Accounts payable$6,745 $11,137 Accrued compensation18,358 24,728 Accrued clinical and other research and development costs23,355 22,822 Accrued manufacturing costs5,002 12,779 Operating lease liability, current9,164 8,308 Deferred research and development funding liability, current22,580 14,129 Other accrued costs and current liabilities4,942 8,305 Total current liabilities90,146 102,208 Operating lease liability, less current portion29,686 36,673 Finance lease liability, less current portion5,554 5,615 Deferred research funding and development liability, less current portion4,038 — Total liabilities129,424 144,496 Commitments and contingencies (Note 6)Stockholders' equity:Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024— — Common stock, $0.01 par value; 400,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 146,625,722 shares and 144,220,986 shares issued and outstanding as of September 30, 2025 and December 31,